Tag: IMU

Imugene ASX IMU Phase 1 clinical trial cancer immunotherapy PD1-Vaxx Australia

Imugene obtains two-pronged approval for Phase 1 clinical trial of new cancer immunotherapy PD1-Vaxx

Immuno-oncology company Imugene (ASX: IMU) received a timely regulatory boost courtesy of a second Human Research Ethics Committee (HREC) approval to commence a Phase I clinical trial of its checkpoin...
Imugene ASX IMU PD1-Vaxx immunotherapy antibodies GMP manufacturing toxicology

Imugene’s PD1-Vaxx treatment to be trialled in patients with lung cancer

Immuno-oncology company Imugene (ASX: IMU) is set to advance its PD1-Vaxx cancer immunotherapy by trialling the treatment in patients with non-small cell lung cancer. In an update to the market, th...
Imugene ASX IMU HER-Vaxx immunotherapy patent United States

Imugene granted HER-Vaxx immunotherapy patent in the United States

Imugene (ASX: IMU) has received a strong boost in protecting its intellectual property for the next 16 years after the US Patent and Trademark Office (USPTO) granted the immuno-oncology company with a...
Immunge ASX IMU US Department Defense City Hope gastric cancer

Researchers to study Imugene’s cancer therapy following US Department of Defense grant

Immuno-oncology company Imugene’s (ASX: IMU) oncolytic virotherapy (OV) drug will receive a boost after City of Hope researchers received a US Department of Defense grant to study the drug in gastric ...
Imugene ASX IMU cancer vaccine tumour oncology

Imugene unveils swathe of positive data on cancer vaccine trials

Clinical stage immuno-oncology company Imugene (ASX: IMU) has presented a range of encouraging trial results on its cancer vaccine programs to thousands of top-level scientists and clinicians at the r...
Imugene ASX IMU endpoints Phase 1b gastric cancer immuno-oncology trial HER-Vaxx vaccine

Imugene’s Phase 1b HER-Vaxx cancer trial meets endpoints, reports positive results

Clinical stage immuno-oncology company Imugene (ASX: IMU) has reported positive top-line results from a Phase 1b clinical study of its HER-Vaxx gastric cancer vaccine in patients expressing the HER2 t...
Imugene ASX IMU Phase 2 gastric cancer trial HER-Vaxx

Imugene receives timely tax rebate to assist ongoing gastric cancer trials

Immuno-oncology company Imugene (ASX: IMU) is set to move into the next phase of trials for its proprietary cancer vaccine, known as HER-Vaxx. The company said that it is now preparing to commence ...
Imugene ASX IMU HER-Vaxx clinical trials cancer vaccine

Imugene completes recruitment for HER-Vaxx clinical trials

Australian medical biotech company Imugene (ASX: IMU) has completed the recruitment of HER-2 gastric cancer patients for the Phase 1b clinical trial of its HER-Vaxx cancer vaccine. The sequential d...
Imugene ASX IMU cancer vaccine positive results pre-clinical trials colorectal colon

Positive results in pre-clinical trials for Imugene’s cancer vaccine

Australian biopharmaceutical company Imugene (ASX: IMU) has reported “superior cancer growth inhibition” from a newly-acquired checkpoint inhibitor cancer vaccine, during preclinical trials with an ex...
Imugene ASX IMU captial raise cancer vaccine licence

Imugene to raise A$20.1m, secures cancer vaccine licence

Imugene (ASX: IMU) has received about A$12 million in commitments from institutional and sophisticated investors, as part of a A$20 million capital raising it says will fully fund its expanded clinica...
Imugene ASX IMU arginine modulator drug candidate melanoma cancer

Imugene makes inroads into melanoma resistance via arginine drug candidate

Medical biotech company Imugene (ASX: IMU) has revealed that its clinical stage arginine modulator drug candidate has demonstrated “anti-tumour activity in 12 different cancer mouse models of the most...
Imugene ASX IMU mimotope cancer vaccine

Imugene readies ground-breaking mimotope cancer vaccine

Following 18 months of gruelling research, Imugene (ASX: IMU) has finally completed the early development of a new mimotope vaccine, aiming to treat a wide variety of cancers in the human body, and ta...
Imugene ASX IMU cancer vaccine gastric cancer trial

Imugene’s cancer vaccine yields promising results in gastric cancer trial

Immuno-oncology company Imugene (ASX: IMU) has yielded “promising” results while trialling its cancer vaccine in its gastric cancer clinical study. The HER-Vaxx cancer vaccine was developed to use ...
Imugene Limited IMU ASX first patient dosing HER-Vaxx gastric cancer study

Imugene commences first patient dosing for HER-Vaxx gastric cancer study

Imugene Limited (ASX: IMU) has commenced first patient dosing of the Phase 1b/2 clinical study of its HER-Vaxx immunotherapy in gastric cancer. Key Highlights: Imugene has successfully commenc...